Learn what Wall Street already knows in our "Billion Dollar Secret" guide.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
Test Menu Expansion by LabCorp
BDX LH COO
Laboratory Corporation of America Holdings ( LH - Analyst Report) recently launched an expanded testing menu to diagnose, treat and evaluate the course of Inflammatory Bowel Disease (IBD). The expanded test menu supplements the company’s wide portfolio of digestive disease testing. About IBD
Gastrointestinal (GI) tract illnesses are not easily identifiable due to non-specific symptoms in the patient. IBD is one the most prevalent GI tract disorders which causes acute discomfiture. Ulcerative colitis and Crohn’s disease are the two clinical manifestations of IBD. These forms of IBD are difficult to treat due to the use of immunosuppressant therapies, biological drugs and/or surgery.
LabCorp’s expanded testing profile will enable clinicians to diagnose and treat patients suffering from IBD. Further, the company’s latest offering can distinguish between the two clinical forms of IBD. The expanded testing menu constitutes specific antibody markers for both ulcerative colitis and Crohn’s disease. The inclusion of the markers enhances diagnostic sensitivity and also predicts the likelihood of the severity of the disease in patients. Our Take
LabCorp is continuously working on portfolio expansion to drive top line. This should help the company to capture larger share of the $60 billion domestic lab market.
With a burgeoning healthcare expenditure, anticipated expansion in healthcare coverage, demographic tailwinds and cost efficiency among others, there is no dearth of positive catalysts for LabCorp. Given this backdrop, we expect the new addition to its portfolio to garner incremental revenues.
However, challenging volume environments for testing laboratories and utilization weaknesses across the healthcare sector are a cause of concern. Further, margins continue to remain under pressure. Although the company’s share buyback activity might provide some cushion, we remain watchful of the poor bottom-line guidance for 2013 which implies that industry trends are not expected to improve in the near-term.
Accordingly, the stock carries a Zacks Rank #3 (Hold). However, other healthcare stocks such as Becton, Dickinson and Company ( BDX - Analyst Report) , The Cooper Companies ( COO - Analyst Report) and MWI Veterinary Supply are expected to do well. These stocks carry a Zacks Rank #2 (Buy).